Data collected between May 4 and May 9, 2026 through Spherix Global Insights’ Launch Dynamix™ service suggest Bristol Myers Squibb’s Sotyktu (deucravacitinib) is beginning to gain traction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results